| HOME >> BIOLOGY >> TECHNOLOGY |
- Presentations highlight Palomid 529 as an anti-angiogenic, anti-tumor
Akt/mTOR inhibitor -
JAMAICA PLAIN, Mass., Apr 15 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. today announced it has presented three presentations at the 2008 annual meeting of the American Association for Cancer Research describing cancer drug Palomid 529 (P529).
P529 is a non-steroidal, synthetic, small molecule dual acting anti-angiogenic and direct anti-tumor agent created through computational design, synthetic and medicinal chemistry, the result of three generations of Palomid design work. Palomid's broad activity as an anti-angiogenic agent and anti-tumor agent is shown to reside in its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway as a TORC1/TORC2 inhibitor.
The first of the three presentations, "Palomid 529, a Dual Acting Anti-angiogenic and Direct Anti-tumor Agent Affecting the PI3K/Akt/mTor Pathway," was be given by Dr. David Sherris, President and CEO of Paloma Pharmaceuticals. The second presentation, "Palomid 529 (P529) inhibits tumor angiogenesis and selectively inhibits the Akt but not MAPK signaling pathways," was given by the laboratory of Dr. Laura E. Benjamin of the Department of Pathology and Center for Vascular Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. The last presentation, "Enhancement of radiotherapy in prostate cancer by the dibenzo[c]chrom-6-one derivative P529" was given by the laboratory of Dr. Alfonso Calvo of the Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
"mTOR and the protein complexes mTORC1 and mTORC2 are excellent targets for cancer therapy because they provide important signaling links to tumor and stromal pathways dysregulated in many cancers," said Dr. Benjamin whose work has helped to understand the mechanism of action of P529.
"We have shown in a series of prost
'/>"/>
| SOURCE Paloma Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |